Influence of the mutation status of NPM1 or FLT3-ITD on early response parameters in all patients
| End point . | NPM1+, n = 299 . | NPM1−, n = 299 . | FLT3-ITD+, n = 174 . | FLT3-ITD−, n = 424 . | P,NPM1+ vs NPM1− . | P,FLT3-ITD+ vs FLT3-ITD− . |
|---|---|---|---|---|---|---|
| Day-16 blasts less than 10% | ||||||
| Rate, % | 80 | 57 | 71 | 67 | < .001 | .498 |
| No. of patients | 238 | 171 | 123 | 286 |
| End point . | NPM1+, n = 299 . | NPM1−, n = 299 . | FLT3-ITD+, n = 174 . | FLT3-ITD−, n = 424 . | P,NPM1+ vs NPM1− . | P,FLT3-ITD+ vs FLT3-ITD− . |
|---|---|---|---|---|---|---|
| Day-16 blasts less than 10% | ||||||
| Rate, % | 80 | 57 | 71 | 67 | < .001 | .498 |
| No. of patients | 238 | 171 | 123 | 286 |
| . | NPM1+, n = 352 . | NPM1−, n = 338 . | FLT3-ITD+, n = 200 . | FLT3-ITD−, n = 490 . | . | . |
|---|---|---|---|---|---|---|
| CR | ||||||
| Rate, % | 75 | 57 | 68 | 65 | < .001 | .480 |
| No. of patients | 264 | 191 | 136 | 319 |
| . | NPM1+, n = 352 . | NPM1−, n = 338 . | FLT3-ITD+, n = 200 . | FLT3-ITD−, n = 490 . | . | . |
|---|---|---|---|---|---|---|
| CR | ||||||
| Rate, % | 75 | 57 | 68 | 65 | < .001 | .480 |
| No. of patients | 264 | 191 | 136 | 319 |
| . | NPM1+/FLT3-ITD−, n = 177 . | NPM1+/FLT3-ITD+, n = 122 . | NPM1−/FLT3-ITD−, n = 247 . | NPM1−/FLT3-ITD+, n = 52 . | . | P . |
|---|---|---|---|---|---|---|
| Day-16 blasts less than 10% | ||||||
| Rate, % | 80 | 79 | 58 | 52 | < .001 | |
| No. of patients | 142 | 96 | 144 | 27 |
| . | NPM1+/FLT3-ITD−, n = 177 . | NPM1+/FLT3-ITD+, n = 122 . | NPM1−/FLT3-ITD−, n = 247 . | NPM1−/FLT3-ITD+, n = 52 . | . | P . |
|---|---|---|---|---|---|---|
| Day-16 blasts less than 10% | ||||||
| Rate, % | 80 | 79 | 58 | 52 | < .001 | |
| No. of patients | 142 | 96 | 144 | 27 |
| . | NPM1+/FLT3-ITD−, n = 211 . | NPM1+/FLT3-ITD+, n = 141 . | NPM1−/FLT3-ITD−, n = 279 . | NPM1−/FLT3-ITD+, n = 59 . | . | . |
|---|---|---|---|---|---|---|
| CR | ||||||
| Rate, % | 77 | 71 | 56 | 58 | < .001 | |
| No. of patients | 163 | 100 | 156 | 34 | ||
| ED | ||||||
| Rate, % | 13 | 10 | 17 | 22 | .104 | |
| No. of patients | 28 | 14 | 46 | 13 | ||
| PL | ||||||
| Rate, % | 5 | 9 | 15 | 12 | .003 | |
| No. of patients | 10 | 13 | 42 | 7 | ||
| Hypoplasia | ||||||
| Rate, % | 5 | 10 | 13 | 9 | .032 | |
| No. of patients | 10 | 14 | 35 | 5 |
| . | NPM1+/FLT3-ITD−, n = 211 . | NPM1+/FLT3-ITD+, n = 141 . | NPM1−/FLT3-ITD−, n = 279 . | NPM1−/FLT3-ITD+, n = 59 . | . | . |
|---|---|---|---|---|---|---|
| CR | ||||||
| Rate, % | 77 | 71 | 56 | 58 | < .001 | |
| No. of patients | 163 | 100 | 156 | 34 | ||
| ED | ||||||
| Rate, % | 13 | 10 | 17 | 22 | .104 | |
| No. of patients | 28 | 14 | 46 | 13 | ||
| PL | ||||||
| Rate, % | 5 | 9 | 15 | 12 | .003 | |
| No. of patients | 10 | 13 | 42 | 7 | ||
| Hypoplasia | ||||||
| Rate, % | 5 | 10 | 13 | 9 | .032 | |
| No. of patients | 10 | 14 | 35 | 5 |
Definition of early response parameters: complete remission (CR) indicates normocellular BM with less than 5% blasts, more than 1500 neutrophils/μL, and more than 100 000 platelets/μL; early death (ED), death after fewer than 7 days after completion of first induction; persistent leukemia (PL), 5% or more blasts in the BM with a leukemic phenotype (eg, Auer rods) after complete induction treatment; and hypoplasia without AML, less than 1000 neutrophils/μL, less than 100 000 platelets/μL, and no blasts.
The analyses were performed in cross tables using 2-sided exact Fisher test.